Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: A case report.

Document Type

Article

Publication Date

6-1-2021

Publication Title

Transplant infectious disease : an official journal of the Transplantation Society

Abstract

Patients receiving extracorporeal membrane oxygenation (ECMO) may display large decreases in drug concentrations due to increases in volume of distribution and drug binding to ECMO circuits, tubing, oxygenator, and coating materials. We report a case of a critically ill male with a 10-month status post-deceased donor renal transplant and being treated with voriconazole for suspected aspergillosis. Initially, multiple dose increases, up to 11.3 mg/kg/dose, were required while on ECMO therapy to obtain goal voriconazole trough concentrations between 2 and 5.5 mcg/mL. The patient's voriconazole dose requirement subsequently decreased to 7.3 mg/kg/dose after ECMO discontinuation, which represented a 45% reduction in voriconazole dose requirement. Based upon this experience, voriconazole appears to bind to artificial surfaces on ECMO devices. In addition to close monitoring of trough levels, it may be appropriate to empirically reduce the voriconazole dose in patients after ECMO discontinuation.

Volume

23

Issue

3

First Page

e13545

DOI

10.1111/tid.13545

ISSN

1399-3062

PubMed ID

33316840

Link to Full Text

Share

COinS